47 results on '"F. Deho’"'
Search Results
2. Incongruence between TURB and radical cystectomy findings in terms of histological variant identification: Analysis of all potential clinical risk factors
- Author
-
M. Bandini, E. Zaffuto, S. Scuderi, A. Salonia, R. Lucianò, F. Pederzoli, G. Burgio, M. Moschini, V. Scattoni, F. Deho’, A. Briganti, F. Montorsi, R. Colombo, A. Necchi, and A. Gallina
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2020
- Full Text
- View/download PDF
3. Impact of histological variants in node positive patients treated with radical cystectomy for bladder cancer
- Author
-
M. Bandini, E. Zaffuto, S. Scuderi, A. Salonia, R. Lucianò, F. Pederzoli, S. Zamboni, L. Afferi, G. Burgio, M. Moschini, F. Deho’, R. Bertini, A. Briganti, F. Montorsi, R. Colombo, A. Necchi, and A. Gallina
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2020
- Full Text
- View/download PDF
4. The implementation of a prospective standardized postoperative complication system according to the EAU guidelines is associated with a decrease in the rate of adverse postoperative outcomes over time
- Author
-
G. Rosiello, N. Fossati, G. Gandaglia, V. Cucchiara, L. Nocera, E. Zaffuto, S. Scuderi, F. Barletta, D. Robesti, V. Mirone, N. Longo, A. Rizzo, D. Cannoletta, E. Zito, A. Gallina, F. Deho’, S. Comana, A. Stabile, C. Bravi, N. Suardi, F. Montorsi, and A. Briganti
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2020
- Full Text
- View/download PDF
5. Predictors of phosphodiesterase type 5 Inhibitors (PDE5I)-discontinuation – Is a previous PDE5I-exposure at first clinical evaluation related with a higher PDE5I-drop-out risk?
- Author
-
N. Schifano, P. Capogrosso, G. Fallara, E. Pozzi, F. Belladelli, L. Candela, C. Corsini, M. Raffo, A. Costa, D. Cignoli, A. D'Arma, L. Boeri, E. Ventimiglia, R. Matloob, V. Mirone, F. Deho', F. Montorsi, and A. Salonia
- Subjects
Urology - Published
- 2022
6. Trends of utilization and comparison between AMS® vs. Coloplast Titan® Inflatable Penile Prostheses (IPPs) in Italy – results from a national registry (INSIST-ED)
- Author
-
N. Schifano, G. Antonini, C. Bettocchi, F. Colombo, G. Liguori, S. Fiordelise, A. Vitarelli, M. Silvani, M. Paradiso, C. Ceruti, F. Varvello, F. Palumbo, A. Avolio, D. Pozza, G. Franco, M. Bitelli, E. Conti, E. Caraceni, E. Pescatori, A. Salonia, A. Palmieri, F. Deho', and P. Capogrosso
- Subjects
Urology - Published
- 2022
7. Drugs associated the most with male-factor infertility: assessment of the 2010–2020 food and drug administration (FDA) pharmacovigilance database
- Author
-
F. Schifano, N. Schifano, P. Capogrosso, L. Boeri, E.P. Pozzi, F. Belladelli, S. Chiappini, F. Castiglione, F. Deho’, F. Montorsi, and A. Salonia
- Subjects
Urology - Published
- 2021
8. Is finasteride intake associated with penile curvature/peyronie’s disease? Assessment of both the food and drug administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
- Author
-
N. Schifano, P. Capogrosso, L. Boeri, E.P. Pozzi, F. Belladelli, S. Chiappini, F. Castiglione, F. Deho’, F. Montorsi, A. Salonia, and F. Schifano
- Subjects
Urology - Published
- 2021
9. Medications mostly associated with priapism events: assessment of the 2015–2020 food and drug administration (FDA) pharmacovigilance database entries
- Author
-
N. Schifano, P. Capogrosso, L. Boeri, E.P. Pozzi, F. Belladelli, S. Chiappini, F. Castiglione, F. Deho’, F. Schifano, F. Montorsi, and A. Salonia
- Subjects
Urology - Published
- 2021
10. Do performance characteristics of multi-parametric MRI of the prostate change according to patient age? Clinical implications for age-tailored biopsy approaches
- Author
-
A. Stabile, P. Dell’Oglio, M. Soligo, F. De Cobelli, G. Gandaglia, E. Zaffuto, G. Fallara, N. Fossati, L. Boeri, S. Scuderi, F. Deho’, A. Esposito, A. Del Maschio, J. Karnes, F. Montorsi, and A. Briganti
- Subjects
Urology - Published
- 2019
11. Is it clinically useful to screen all patients with LUTS for erectile dysfunction?
- Author
-
P. Capogrosso, E. Ventimiglia, L. Boeri, E. Pozzi, N. Schifano, F. Chierigo, F. Belladelli, W. Cazzaniga, C. Abbate, F. Deho’, F. Gaboardi, F. Montorsi, and A. Salonia
- Subjects
Urology - Published
- 2019
12. Should we rely on multiparametric MRI of the prostate performed at non-academic centres? Implications for optimized target biopsy approaches
- Author
-
A. Stabile, F. Barletta, P. Dell’Oglio, F. De Cobelli, A. Esposito, G. Brembilla, G. Gandaglia, N. Fossati, E. Zaffuto, F. Deho’, U. Capitanio, N. Suardi, A. Del Maschio, F. Montorsi, and A. Briganti
- Subjects
Urology - Published
- 2019
13. The ageing male and erectile dysfunction
- Author
-
F, Montorsi, A, Briganti, A, Salonia, F, Deho', G, Zanni, A, Cestari, G, Guazzoni, P, Rigatti, C, Stief, Montorsi, Francesco, Briganti, Alberto, Salonia, Andrea, Deho', F, Zanni, G, Cestari, A, Guazzoni, G, Rigatti, P, and Stief, C.
- Subjects
Aged, 80 and over ,Male ,Erectile Dysfunction ,Practice Guidelines as Topic ,Age Factors ,Humans ,Middle Aged ,Aged - Abstract
Erectile dysfunction is common in the ageing man and reliable therapies are needed. The pathophysiology of erectile dysfunction in this group mainly includes chronic ischaemia, which triggers the deterioration of cavernosal smooth muscle and the development of corporeal fibrosis. Assessing the ageing man with erectile dysfunction who seeks medical treatment should comprise a thorough medical and sexual history, a systemic and focused physical examination and selected blood tests. Oral drug therapy represents a safe and effective option for most ageing men.
- Published
- 2003
14. Pharmacological management of erectile dysfunction
- Author
-
F, Montorsi, A, Salonia, F, Deho', A, Cestari, G, Guazzoni, P, Rigatti, C, Stief, Montorsi, Francesco, Salonia, Andrea, Deho', F, Cestari, A, Guazzoni, G, Rigatti, P, and Stief, C.
- Subjects
Male ,Apomorphine ,Phosphodiesterase Inhibitors ,Triazines ,Vasodilator Agents ,Imidazoles ,Administration, Oral ,Piperazines ,Sildenafil Citrate ,Injections ,Tadalafil ,Drug Combinations ,Erectile Dysfunction ,Vardenafil Dihydrochloride ,Purines ,Papaverine ,Humans ,Sulfones ,Alprostadil ,Phentolamine ,Adrenergic alpha-Antagonists ,Carbolines - Abstract
Erectile dysfunction (ED) is a common medical condition that affects the sexual life of millions of men worldwide. Many drugs are now available for treating ED; oral pharmacotherapy represents the first-line option for most patients with ED. Sildenafil, an inhibitor of the enzyme phosphodiesterase type 5, is currently the most widely prescribed oral agent and has a very satisfactory efficacy-safety profile in all patient categories. Apomorphine SL is a dopamine D1- and D2-receptor agonist which has recently been approved for marketing in Europe. It is best selected for treating patients with mild to moderate ED. Vardenafil and tadalafil are new phosphodiesterase type 5 inhibitors which are expected to be approved this year. Both of them have significant positive efficacy-safety profiles. Patients who do not respond to oral pharmacotherapy or who cannot use it are good candidates for intracavernosal and intraurethral therapy. Alprostadil is the most widely used drug, both for injection therapy and for the intraurethral route. The efficacy of second-line treatment is high but the attrition rate remains significant.
- Published
- 2003
15. 75 POST-OPERATIVE ORGASMIC FUNCTION INCREASES OVERTIME IN PATIENTS SUBMITTED TO BILATERAL NERVE SPARING OPEN RADICAL PROSTATECTOMY
- Author
-
A. Salonia, A. Gallina, A. Briganti, L.F. Da Pozzo, R. Colombo, G. Zanni, F. Deho, L. Rocchini, A. Cestari, G. Guazzoni, P. Rigatti, and F. Montorsi
- Subjects
Urology - Published
- 2009
16. The ageing male and erectile dysfunction.
- Author
-
Montorsi, F., Briganti, A., Salonia, A., F. Deho', A., G. Zanni, A., A. Cestari, A., G. Guazzoni, A., P. Rigatti, A., and C. Stief, A.
- Subjects
TREATMENT of sexual dysfunction ,OLDER men ,PHYSIOLOGICAL aspects of aging ,IMPOTENCE ,MEDICAL care - Abstract
Erectile dysfunction is common in the ageing man and reliable therapies are needed. The pathophysiology of erectile dysfunction in this group mainly includes chronic ischaemia, which triggers the deterioration of cavernosal smooth muscle and the development of corporeal fibrosis. Assessing the ageing man with erectile dysfunction who seeks medical treatment should comprise a thorough medical and sexual history, a systemic and focused physical examination and selected blood tests. Oral drug therapy represents a safe and effective option for most ageing men. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
17. Risk of unfavorable outcomes after penile prosthesis implantation – results from a national registry (INSIST-ED)
- Author
-
P. Capogrosso, E. Pescatori, C. Bettocchi, F. Colombo, G. Liguori, S. Fiordelise, A. Vitarelli, M. Silvani, N. Mondaini, M. Paradiso, C. Ceruti, F. Varvello, F. Palumbo, A. Avolio, G. Antonini, D. Pozza, G. Franco, M. Bitelli, E. Conti, E. Caraceni, A. Salonia, A. Palmieri, and F. Deho
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2020
- Full Text
- View/download PDF
18. Glans ischaemia after circumcision in adult males: A two-patient case series and a narrative review of the literature.
- Author
-
Schifano N, Capogrosso P, Villano A, Baldini S, Antonini G, and Deho' F
- Subjects
- Humans, Male, Adult, Young Adult, Postoperative Complications etiology, Circumcision, Male adverse effects, Ischemia etiology, Penis blood supply
- Abstract
Introduction: Glans necrosis after circumcision is an exceedingly rare complication among adult males, with only a handful of cases being reported in the literature., Materials and Methods: We present here two cases of glans ischaemia observations after circumcision in both a 19-year-old and a 26-year-old patient; both were managed with oral medications in the outpatient setting, with complete restitutio-ad-integrum. A narrative review of the literature was also performed to better describe the possible predisposing factors; the treatment/management options; and the typical outcomes among the adult males experiencing with this complication., Results: Penile dorsal anaesthetic blocks, monopolar cautery usage and compressive wound dressing are all reported to play a role as co-factors for glans ischaemia after circumcision, hence their adoption should be mindful. There is no consensus on the management of ischaemia of the glans after male circumcision., Conclusions: The favourable outcomes being reported for most of the literature cases of glans ischaemia after circumcision among adults despite the adoption of diverse empirical therapeutic strategies suggest that the role of the proactive management may be questionable., Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
19. Medications mostly associated with priapism events: assessment of the 2015-2020 Food and Drug Administration (FDA) pharmacovigilance database entries.
- Author
-
Schifano N, Capogrosso P, Boeri L, Fallara G, Cakir OO, Castiglione F, Alnajjar HM, Muneer A, Deho' F, Schifano F, Montorsi F, and Salonia A
- Subjects
- Male, United States, Humans, United States Food and Drug Administration, Pharmacovigilance, Phosphodiesterase 5 Inhibitors adverse effects, Priapism chemically induced, Priapism drug therapy, Trazodone
- Abstract
A range of drugs have a direct role in triggering ischaemic priapism. We aimed at identifying: a) which medications are associated with most priapism-reports; and, b) within these medications, comparing their potential to elicit priapism through a disproportionality analysis. The FDA Adverse Event Reporting System (FAERS) database was queried to identify those drugs associated the most with priapism reports over the last 5 years. Only those drugs being associated with a minimum of 30 priapism reports were considered. The Proportional Reporting Ratios (PRRs), and their 95% confidence intervals were computed. Out of the whole 2015-2020 database, 1233 priapism reports were identified, 933 of which (75.7%) were associated with 11 medications with a minimum of 30 priapism-reports each. Trazodone, olanzapine and tadalafil showed levels of disproportionate reporting, with a PRR of 9.04 (CI95%: 7.73-10.58), 1.55 (CI95%: 1.27-1.89), and 1.42 (CI95%: 1.10-1.43), respectively. Most (57.5%) of the reports associated with the phosphodiesterase type 5 inhibitors (PDE5Is) were related with concomitant priapism-eliciting drugs taken at the same time and/or inappropriate intake/excessive dosage. Patients taking trazodone and/or antipsychotics need to be aware of the priapism-risk; awareness among prescribers would help in reducing priapism-related detrimental sequelae; PDE5I-intake is not responsible for priapism by itself, when appropriate medical supervision is provided., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
20. Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases.
- Author
-
Schifano N, Capogrosso P, Boeri L, Fallara G, Chiappini S, Rewhorn M, Cakir OO, Harvey H, Castiglione F, Alnajjar HM, Muneer A, Deho' F, Schifano F, Montorsi F, and Salonia A
- Subjects
- Male, United States, Humans, Finasteride adverse effects, Pharmacovigilance, United States Food and Drug Administration, Adverse Drug Reaction Reporting Systems, Databases, Factual, Penile Diseases, Penile Induration, Drug-Related Side Effects and Adverse Reactions epidemiology
- Abstract
A limited number of studies have described patients on finasteride showing findings which were consistent with Peyronie's disease (PD). We aimed to detect a pharmacovigilance signal of possible association between finasteride and PD-related clinical features. The Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried to identify the ten drugs which were associated the most with the adverse drug reactions (ADRs) recorded as "penile curvature" and/or "Peyronie's disease". A similar analysis, including the same drugs, was carried out for the EMA (European Medicines Agency) EudraVigilance (EV) database. Descriptive data have been analyzed, and Proportional Reporting Ratios (PRRs) have been computed against the other nine drugs of the database. Overall, 860 reports of "penile curvature" and/or "Peyronie's disease", were identified in the FAERS database, 214 of which (24.9%) were associated with finasteride. Most reports (56.9%) were submitted by healthcare professionals. Where a treatment-indication was stated, the vast majority of reports (176/210; 83.8%) were associated with androgenetic alopecia. The outcome of most ADRs was "serious" (82.2%), with 96 ADRs resulting in levels of permanent disability. For 97/214 individual cases, penile curvature/PD reports were not part of a syndromic cluster suggestive of post-finasteride syndrome (PFS). The PRR resulted 6.6 (95% CI: 5.6-7.8) and 11.8 (95% CI: 9.08-15.33), respectively, in the FAERS and in the EV databases. Notwithstanding the related limitations and biasing factors of pharmacovigilance studies based on spontaneous reporting, the PRR values here identified should be interpreted as strong signals of disproportionality. These findings, per se, are however not useful to confirm any causal association. Clinical studies are needed to investigate on the possible role for finasteride in causing PD-related clinical features, an hypothesis which remains highly speculative due to the very questionable quality of present data., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
21. Perspective on the PHOENIX trial: prospective registry for patients undergoing penile prosthesis implantation for male erectile dysfunction in multiple European centers.
- Author
-
van Renterghem K and Deho F
- Subjects
- Humans, Male, Patient Satisfaction, Registries, Erectile Dysfunction surgery, Penile Implantation, Penile Prosthesis
- Published
- 2023
- Full Text
- View/download PDF
22. Contemporary Outcomes of Patients With Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Implications for Clinical Trial Design. Letter.
- Author
-
Montorsi F, Moschini M, Necchi A, Deho F, Gandaglia G, and Briganti A
- Subjects
- Administration, Intravesical, BCG Vaccine therapeutic use, Clinical Trials as Topic, Humans, Mycobacterium bovis, Urinary Bladder Neoplasms drug therapy
- Published
- 2021
- Full Text
- View/download PDF
23. New Insight into Molecular and Hormonal Connection in Andrology.
- Author
-
Francomano D, Sanguigni V, Capogrosso P, Deho F, and Antonini G
- Subjects
- Andrology, Animals, Humans, Male, Androgens metabolism, Cytokines metabolism, Sexual Behavior, Spermatogenesis
- Abstract
Hormones and cytokines are known to regulate cellular functions in the testes. These biomolecules induce a broad spectrum of effects on various level of spermatogenesis, and among them is the modulation of cell junction restructuring between Sertoli cells and germ cells in the seminiferous epithelium. Cytokines and androgens are closely related, and both correct testicular development and the maintenance of spermatogenesis depend on their function. Cytokines also play a crucial role in the immune testicular system, activating and directing leucocytes across the endothelial barrier to the inflammatory site, as well as in increasing their adhesion to the vascular wall. The purpose of this review is to revise the most recent findings on molecular mechanisms that play a key role in male sexual function, focusing on three specific molecular patterns, namely, cytokines, miRNAs, and endothelial progenitor cells. Numerous reports on the interactions between the immune and endocrine systems can be found in the literature. However, there is not yet a multi-approach review of the literature underlying the role between molecular patterns and testicular and sexual function.
- Published
- 2021
- Full Text
- View/download PDF
24. The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis.
- Author
-
Ferro M, Del Giudice F, Carrieri G, Busetto GM, Cormio L, Hurle R, Contieri R, Arcaniolo D, Sciarra A, Maggi M, Porpiglia F, Manfredi M, Fiori C, Antonelli A, Tafuri A, Bove P, Terrone C, Borghesi M, Costantini E, Iliano E, Montanari E, Boeri L, Russo GI, Madonia M, Tedde A, Veccia A, Simeone C, Liguori G, Trombetta C, Brunocilla E, Schiavina R, Dal Moro F, Racioppi M, Vartolomei MD, Longo N, Spirito L, Crocetto F, Cantiello F, Damiano R, Di Stasi SM, Marchioni M, Schips L, Parma P, Carmignani L, Conti A, Soria F, Gontero P, Barone B, Deho F, Zaffuto E, Papalia R, Scarpa RM, Pagliarulo V, Lucarelli G, Ditonno P, Botticelli FMG, Musi G, Catellani M, and de Cobelli O
- Abstract
Background: To investigate the impact of COVID-19 outbreak on the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC)., Methods: A retrospective analysis was performed using an Italian multi-institutional database of TURBT patients with high-risk urothelial NMIBC between January 2019 and February 2021, followed by Re-TURBT and/or adjuvant intravesical BCG., Results: A total of 2591 patients from 27 institutions with primary TURBT were included. Of these, 1534 (59.2%) and 1056 (40.8%) underwent TURBT before and during the COVID-19 outbreak, respectively. Time between diagnosis and TURBT was significantly longer during the COVID-19 period (65 vs. 52 days, p = 0.002). One thousand and sixty-six patients (41.1%) received Re-TURBT, 604 (56.7%) during the pre-COVID-19. The median time to secondary resection was significantly longer during the COVID-19 period (55 vs. 48 days, p < 0.0001). A total of 977 patients underwent adjuvant intravesical therapy after primary or secondary resection, with a similar distribution across the two groups ( n = 453, 86% vs. n = 388, 86.2%). However, the proportion of the patients who underwent maintenance significantly differed (79.5% vs. 60.4%, p < 0.0001)., Conclusions: The COVID-19 pandemic represented an unprecedented challenge to our health system. Our study did not show significant differences in TURBT quality. However, a delay in treatment schedule and disease management was observed. Investigation of the oncological impacts of those differences should be advocated.
- Published
- 2021
- Full Text
- View/download PDF
25. Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
- Author
-
Montorsi F, Stabile A, Gandaglia G, Fossati N, Deho' F, Gallina A, and Briganti A
- Subjects
- Anesthesia, Local, Humans, Image-Guided Biopsy, Male, Prospective Studies, Multiparametric Magnetic Resonance Imaging, Prostatic Neoplasms diagnostic imaging
- Published
- 2021
- Full Text
- View/download PDF
26. Management of Renal Cell Carcinoma With Extensive Caval Thrombosis Utilizing a Temporary Atrial Caval Filter Through a Combined Endovascular and Open Surgical Technique.
- Author
-
Fontana F, Deho F, Piacentino F, Curti M, Capogrosso P, Coppola A, Cocozza E, Tozzi M, and Venturini M
- Subjects
- Aged, Carcinoma, Renal Cell diagnostic imaging, Carcinoma, Renal Cell pathology, Device Removal, Humans, Kidney Neoplasms diagnostic imaging, Kidney Neoplasms pathology, Male, Neoplasm Invasiveness, Treatment Outcome, Vena Cava, Inferior diagnostic imaging, Vena Cava, Inferior pathology, Venous Thrombosis diagnostic imaging, Venous Thrombosis pathology, Carcinoma, Renal Cell surgery, Embolization, Therapeutic, Kidney Neoplasms surgery, Nephrectomy, Prosthesis Implantation instrumentation, Thrombectomy instrumentation, Vena Cava Filters, Vena Cava, Inferior surgery, Venous Thrombosis surgery
- Abstract
The most common cause of neoplastic thrombotic infiltration of the inferior vena cava is renal cell carcinoma (RCC). In the present report we described a case of a patient with massive RCC and extensive neoplastic thrombosis reaching the retrohepatic tract of the inferior vena cava. After a discussion in a multidisciplinary team meeting we decided to perform a radical nephrectomy with vena cava thrombectomy along with the support of a novel removable vena cava filter in order to avoid thromboembolism during the surgical procedure. Furthermore, a preoperative renal artery embolization with a non-adhesive liquid embolic agent was performed ahead of the surgical procedure in order to reduce the risk of intraoperative bleeding. The surgical procedure performed the day after was based on a hybrid endovascular-surgical approach consisting in nephrectomy, liver derotation, cavotomy with the additional use of a novel temporary caval filter, thus reducing the risk of intraoperative thromboembolic dissemination.
- Published
- 2021
- Full Text
- View/download PDF
27. Comparing the Italian and North American prospective registries on penile prosthesis surgery: are there relevant differences in treatment indications and patients' management?
- Author
-
Deho' F, Henry G, Karpman E, Pescatori E, Colombo F, Bettocchi C, Liguori G, Ceruti C, Mondaini N, Fiordelise S, Palmieri A, and Capogrosso P
- Subjects
- Humans, Italy, Male, Middle Aged, North America, Registries, Penile Implantation, Penile Prosthesis
- Abstract
Previous studies have shown discrepancies among countries in terms of treatment indications and patients' management due to different health care policies. Penile prosthesis implantation (PPI) is a highly effective treatment for erectile dysfunction (ED), which may have different accessibility according to the type of health system. We compared clinical characteristics of patients included in two national registries on PPI to investigate the influence of different health care systems on treatment indication and accessibility. The multicenter Italian Nationwide Systematic Inventarization of Surgical Treatment for ED (INSIST-ED) Registry and the multicenter Prospective Registry of Outcomes with Penile Prosthesis for Erectile Restoration (PROPPER), respectively for Italy and North America were considered. Clinical characteristics of patients included in both registries were compared using Wilcoxon Rank Sum test and the Pearson's Chi square test. Patients submitted to PPI in Italy are significantly younger (age: 61.2 vs. 63.8 years; p ≤ 0.001) compared with North America. The majority of patients are treated for post-radical prostatectomy ED in both registries (Italy: 31%; North America: 27%), although diabetes and cardiovascular diseases are more frequent reasons for PPI in the PROPPER registry (p ≤ 0.001), reflecting differences in disease prevalence among countries. In North America a non-hydraulic implant is considered only in 1% of cases as compared with 3% in Italy (p ≤ 0.001). In terms of postoperative management, a compressive surgical dressing (98% vs. 24%; p ≤ 0.001) is a more common strategy in North America. Finally, in Italy most surgeries are performed in a public hospital (82%), while the private setting (70.8%) is more common in North America (p ≤ 0.001). These findings suggest differences in health care systems between Italy and North America. A system like the American one would guarantee easier access to PPI in countries where the National Health System is mainly based on reimbursement to public hospital settings and where patients choosing private settings have to pay by themselves., (© 2020. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2021
- Full Text
- View/download PDF
28. Diagnostic and Interventional Radiology Management of Ureteral Iatrogenic Leakage after Gynecologic Surgery.
- Author
-
Fontana F, Piacentino F, Ossola C, Casarin J, Coppola A, Cromi A, Ierardi AM, Carrafiello G, Basile A, Deho F, Ghezzi F, Carcano G, and Venturini M
- Abstract
Objective: To report safety and efficacy of interventional radiology procedures in the treatment of gynecologic iatrogenic urinary leaks., Methods: A retrospective analysis of iatrogenic ureteral lesions treated between November 2009 to April 2019 was performed. Under ultrasound (US) and fluoroscopy guidance, an attempt to place a ureteral stent and nephrostomy was carried out in the same session using an anterograde percutaneous approach. At the end of any procedure, a fluoroscopic control and a cone-beam CT scan (CBCT) were performed to check the correct placement and functioning of the nephrostomy and DJ stent. In cases of difficult ureteral stent placement via the single anterograde approach, the collaboration of urologists was requested to perform a rendezvous technique, combined with the retrograde approach., Results: DJ stent placement was achieved using the anterograde approach in 12/15 (80.0%) patients and using the retrograde approach in 3/15 cases (20.0%). Moreover, in 3/15 (20.0%) patients, surgical treatment was needed: in one case because of the persistence of ureteral stenosis at 6 months, and in the other two cases due to ureter-vaginal fistula. No major complications were recorded; overall, minor complications occurred in 4/8 patients., Conclusion: Percutaneous minimally invasive treatment of iatrogenic ureteral lesions after gynecological surgery is a safe and effective option.
- Published
- 2021
- Full Text
- View/download PDF
29. Letter - Can micro-ultrasound be the new first-choice test for patients with a suspicion of prostate cancer? RE: Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer, CUAJ, Jan 2021 (with author reply).
- Author
-
Montorsi F, Stabile A, Gandaglia G, Deho F, Gallina A, and Briganti A
- Published
- 2021
- Full Text
- View/download PDF
30. Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.
- Author
-
Bandini M, Ross JS, Raggi D, Gallina A, Colecchia M, Lucianò R, Giannatempo P, Farè E, Pederzoli F, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Deho' F, Ali SM, Madison R, Chung JH, Salonia A, Briganti A, Montorsi F, and Necchi A
- Subjects
- Aged, Antibodies, Monoclonal, Humanized adverse effects, B7-H1 Antigen antagonists & inhibitors, Biomarkers, Tumor genetics, Cystectomy, Female, Humans, Italy epidemiology, Male, Middle Aged, Muscles pathology, Mutation genetics, Neoadjuvant Therapy adverse effects, Neoplasm Invasiveness pathology, Neoplasm Staging, Tumor Burden drug effects, Urinary Bladder Neoplasms epidemiology, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms surgery, Antibodies, Monoclonal, Humanized administration & dosage, B7-H1 Antigen genetics, Neoplasm Invasiveness prevention & control, Urinary Bladder Neoplasms drug therapy
- Abstract
Background: In the PURE-01 study (NCT02736266), we aimed to evaluate the ability to predict the pathologic complete response (pT0N0) after pembrolizumab by using clinical and tumor biomarkers., Methods: In an open-label, single-arm, phase 2 study, 3 courses of 200 mg pembrolizumab preceding radical cystectomy were administered in patients with T2-4aN0M0 muscle-invasive bladder cancer. The analyses included a comprehensive genomic profiling and programmed cell-death-ligand-1 (PD-L1)-combined positive score assessment (CPS; Dako 22C3 antibody) of pre- and posttherapy samples. Multivariable logistic regression analyses evaluated baseline clinical T stage and tumor biomarkers in association with pT0N0 response. Corresponding coefficients were used to develop a calculator of pT0N0 response based on the tumor mutational burden (TMB), CPS, and the clinical T stage. Decision-curve analysis was also performed. All statistical tests were 2-sided., Results: From February 2017 to June 2019, 112 patients with biomarker data were enrolled (105 with complete TMB and CPS data). Increasing TMB and CPS values featured a linear association with logistic pT0N0 probabilities (P = .02 and P = .004, respectively). For low TMB values (≤11 mut/Mb, median value, n = 53), pT0N0 probability was not associated with increasing CPS. Conversely, for high TMB values (>11 mut/Mb, n = 52), pT0N0 was statistically significantly associated with higher CPS (P = .004). The C index of the pT0N0 probability calculator was 0.77. On decision-curve analysis, the net benefit of the model was higher than the "treat-all" option within the clinically meaningful threshold probabilities of 40%-50%., Conclusions: The study presents a composite biomarker-based pT0N0 probability calculator that reveals the complex interplay between TMB and CPS, added to the clinical T stage., (© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
31. Satisfaction rate at 1-year follow-up in patients treated with penile implants: data from the multicentre prospective registry INSIST-ED.
- Author
-
Capogrosso P, Pescatori E, Caraceni E, Mondaini N, Utizi L, Cai T, Salonia A, Palmieri A, and Deho' F
- Subjects
- Aged, Clinical Competence, Follow-Up Studies, Humans, Male, Middle Aged, Penile Implantation, Prospective Studies, Registries, Erectile Dysfunction surgery, Patient Satisfaction, Penile Prosthesis, Prosthesis Design
- Abstract
Objectives: To investigate scores and predictors of patient satisfaction at 1 year after penile prosthesis implantation (PPI) using the validated Quality of Life and Sexuality with Penile Prosthesis (QoLSPP) questionnaire., Patients and Methods: Analyses were performed for 142 patients prospectively included in the national multicentre registry Italian Nationwide Systematic Inventarization of Surgical Treatment for Erectile Dysfunction (INSIST-ED), which provided 1-year follow-up data. Postoperative patient satisfaction was assessed using the validated QoLSPP tool. Linear logistic regression analyses assessed predictors of QoLSPP total and single domain scores, including age at surgery, erectile dysfunction aetiology, type of prosthesis, surgical approach, surgeon experience and complications. Locally weighted regression methods were used to explore the relationship between surgeon experience and QoLSPP scores., Results: Overall, high median functional, relational, social, personal and total QoLSPP scores were reported at 1 year after PPI. Patients implanted with hydraulic devices had higher functional (23 vs 21.5; P = 0.01) and total scores (68 vs 65.5; P = 0.03) than those with a malleable prosthesis. Surgeon experience emerged as the only independent predictor of higher satisfaction scores, depicting a non-linear association with both QoLSPP total and single domain scores (all P < 0.03). Data suggested that the higher the number of procedures per year, the greater the satisfaction scores, reaching a plateau after l5 procedures/year., Conclusions: This study reports high functional and patient satisfaction scores at 1 year after PPI surgery using a dedicated tool for the first time. Better outcomes should be expected for patients treated by surgeons with greater experience., (© 2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
32. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
- Author
-
Stabile A, Dell'Oglio P, De Cobelli F, Esposito A, Gandaglia G, Fossati N, Brembilla G, Cristel G, Cardone G, Deho' F, Losa A, Suardi N, Gaboardi F, Del Maschio A, Montorsi F, and Briganti A
- Subjects
- Aged, Evidence-Based Medicine, Humans, Logistic Models, Male, Middle Aged, Neoplasm Grading, Prospective Studies, Prostate-Specific Antigen, Prostatic Neoplasms pathology, Retrospective Studies, Tertiary Care Centers, Image-Guided Biopsy methods, Magnetic Resonance Imaging methods, Prostatic Neoplasms diagnostic imaging, Ultrasonography, Interventional methods
- Abstract
Background: The ability to identify clinically significant prostate cancer (csPCa) has dramatically improved with the introduction of multiparametric magnetic resonance imaging (mpMRI). Given the growing interest in targeted biopsy and focal therapy, improving our knowledge on the relationship between mpMRI parameters and the ability to predict csPCa multifocality is mandatory., Objective: To assess whether the Prostate Imaging Reporting and Data System (PI-RADS) score for the index lesion (IL) may predict multifocal csPCa undetected by mpMRI., Design, Setting, and Participants: The study included 343 patients who underwent mpMRI of the prostate with subsequent biopsy between 2014 and 2017 at a single tertiary care referral centre., Intervention: Lesions with a PI-RADS v.2 score ≥2 detected at mpMRI (IL) were targeted with a fusion biopsy (Bx) approach (mpMRI-Bx). Moreover, each patient underwent a random extended transrectal ultrasound-guided biopsy (TRUS-Bx) during the same session. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: csPCa outside the IL was defined as disease detected at TRUS-Bx with a Gleason score (GS)≥3+4 and equal to or greater than the GS for the IL. The extent of csPCa detected in target and random cores was reported and stratified according to the GS and PI-RADS score for the IL. The probability of diagnosing csPCa outside the IL according to the PI-RADS score was also assessed in multivariable logistic regression analyses (MVA) after accounting for confounders., Results and Limitations: The detection rate for csPCa outside the IL was 30%. The detection rate for csPCa at TRUS-Bx was 8% for PI-RADS 2, 15% for PI-RADS 3, 36% for PI-RADS 4, and 58% for PI-RADS 5 lesions (p=0.03). Overall, the median length of csPCa found at TRUS-Bx and thus missed at mpMRI was 2.6mm. However, the length significantly increased with PI-RADS score for the IL, and was 1.8, 2.3, 2.8, and 3.8mm for PI-RADS 2, 3, 4, and 5 lesions, respectively (p=0.03). On MVA, PI-RADS 4 (odds ratio [OR] 7.6; p=0.008) and PI-RADS 5 scores (OR 17.3; p<0.001) were independent predictors of the presence of csPCa outside the IL. The study is limited by its retrospective design., Conclusions: Overall, the accuracy of mpMRI in identifying multifocal csPCa is poor, missing low-volume csPCa in approximately 30% of patients. Moreover, the rate and the extent of csPCa undetected by mpMRI significantly increased with the PI-RADS score for the IL, which can thus be considered a proxy for tumour multifocality., Patient Summary: The accuracy of multiparametric magnetic resonance imaging in identifying prostate cancer multifocality is poor. False negative findings were highly related to the PI-RADS score of the index lesion. These findings raise concerns about the indication for targeting the index lesion only when considering prostate biopsy and focal approaches., (Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
33. Lymphadenopathies in patients with renal cell carcinoma: clinical and pathological predictors of pathologically confirmed lymph node invasion.
- Author
-
Capitanio U, Deho' F, Dell'Oglio P, Larcher A, Capogrosso P, Nini A, Carenzi C, Freschi M, Briganti A, Salonia A, Montorsi F, and Bertini R
- Subjects
- Aged, Carcinoma, Renal Cell pathology, Humans, Lymphadenopathy pathology, Lymphatic Metastasis, Middle Aged, Neoplasm Invasiveness, Prognosis, Carcinoma, Renal Cell secondary, Kidney Neoplasms pathology, Lymphadenopathy etiology
- Abstract
Introduction: In renal cell carcinoma (RCC), lymph node status at preoperative imaging is affected by a non-negligible false-positive rate. We aimed to investigate which factors are related to a concordance between clinical suspicion and pathological confirmation of lymph node invasion (LNI)., Methods: At a single tertiary care institution, 2954 RCC patients underwent either partial or radical nephrectomy. For the aim of the study, only clinically positive lymph node cases were included (cN1). Statistical analyses assessed the concordance between preoperative and pathological nodal status., Results: Preoperative axial CT scans revealed 424 (14.4 %) patients showing at least one enlarged lymph node suspected for LNI (cN1). All lymphadenopathies were removed at surgery, and LNI was pathologically confirmed (pN1) in 122 patients (28.8 %). When focusing the analyses on clinical characteristics (variables known before surgery), metastases at diagnosis [OR 3.0 (95 %1.9-4.8), p < 0.001] and tumor size [OR 1.1 (95 % 1.1-1.2), p < 0.001] were the two most informative predictors of concordance between clinical and pathological nodal status. Concordance was also more likely in patients with papillary type II tumors (55.6 %) relative to papillary type I (38.1 %), clear cell (27.7 %) and chromophobe (8.3 %) tumors. At multivariable analyses, none of the considered blood markers resulted to be independently associated with LNI., Conclusions: Roughly 70 % of patients showing a suspected lymph node preoperatively do not show LNI at the final pathological report. Among patients with clinically positive nodes, clinical tumor size and metastases at diagnosis represent the most informative and independent predictors of confirmed LNI at final pathology.
- Published
- 2016
- Full Text
- View/download PDF
34. The use of mannitol in partial and live donor nephrectomy: an international survey.
- Author
-
Cosentino M, Breda A, Sanguedolce F, Landman J, Stolzenburg JU, Verze P, Rassweiler J, Van Poppel H, Klingler HC, Janetschek G, Celia A, Kim FJ, Thalmann G, Nagele U, Mogorovich A, Bolenz C, Knoll T, Porpiglia F, Alvarez-Maestro M, Francesca F, Deho F, Eggener S, Abbou C, Meng MV, Aron M, Laguna P, Mladenov D, D'Addessi A, Bove P, Schiavina R, De Cobelli O, Merseburger AS, Dalpiaz O, D'Ancona FC, Polascik TJ, Muschter R, Leppert TJ, and Villavicencio H
- Subjects
- Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents therapeutic use, Antioxidants administration & dosage, Antioxidants pharmacology, Antioxidants therapeutic use, Dose-Response Relationship, Drug, Health Care Surveys, Humans, Internationality, Kidney drug effects, Mannitol administration & dosage, Mannitol pharmacology, Prospective Studies, Surveys and Questionnaires, Time Factors, Kidney surgery, Kidney Transplantation methods, Living Donors, Mannitol therapeutic use, Nephrectomy methods
- Abstract
Purpose: Animal studies have shown the potential benefits of mannitol as renoprotective during warm ischemia; it may have antioxidant and anti-inflammatory properties and is sometimes used during partial nephrectomy (PN) and live donor nephrectomy (LDN). Despite this, a prospective study on mannitol has never been performed. The aim of this study is to document patterns of mannitol use during PN and LDN., Materials and Methods: A survey on the use of mannitol during PN and LDN was sent to 92 high surgical volume urological centers. Questions included use of mannitol, indications for use, physician responsible for administration, dosage, timing and other renoprotective measures., Results: Mannitol was used in 78 and 64 % of centers performing PN and LDN, respectively. The indication for use was as antioxidant (21 %), as diuretic (5 %) and as a combination of the two (74 %). For PN, the most common dosages were 12.5 g (30 %) and 25 g (49 %). For LDN, the most common doses were 12.5 g (36.3 %) and 25 g (63.7 %). Overall, 83 % of centers utilized mannitol, and two (percent or centers??) utilized furosemide for renoprotection., Conclusions: A large majority of high-volume centers performing PN and LDN use mannitol for renoprotection. Since there are no data proving its value nor standardized indication and usage, this survey may provide information for a randomized prospective study.
- Published
- 2013
- Full Text
- View/download PDF
35. Diagnosis of isolated high-grade prostatic intra-epithelial neoplasia: proposal of a nomogram for the prediction of cancer detection at saturation re-biopsy.
- Author
-
Roscigno M, Scattoni V, Freschi M, Abdollah F, Maccagnano C, Galosi A, Lacetera V, Montironi R, Muzzonigro G, Deho F, Deiana G, Belussi D, Chinaglia D, Montorsi F, and Da Pozzo LF
- Subjects
- Aged, Aged, 80 and over, Biopsy methods, Humans, Male, Middle Aged, Predictive Value of Tests, Prostatic Intraepithelial Neoplasia diagnosis, Prostatic Neoplasms diagnosis, Retrospective Studies, Nomograms, Prostate pathology, Prostatic Intraepithelial Neoplasia pathology, Prostatic Neoplasms pathology
- Abstract
Unlabelled: Study Type--Diagnostic (case series). Level of Evidence 4. What's known on the subject? And what does the study add? Multifocality, age, PSA values, and biopsy protocols regarding the predictive value of high grade PIN have been discussed extensively in the literature. Our study developed for the first time a predictive nomogram that could be helpful for patient counselling and to guide the urologist to perform rPBX after an initial diagnosis of isolated HGPIN., Objective: • To evaluate factors that may predict prostate cancer (PCa) detection after the initial diagnosis of high-grade prostatic intra-epithelial neoplasia (HGPIN) on prostate biopsy (PBx) with six to 24 random cores., Patients and Methods: • We retrospectively evaluated 262 patients submitted from 1998 to 2007 to prostate re-biopsy (rPBx) after an initial HGPIN diagnosis in tertiary academic centres. • HGPIN diagnosis was obtained on initial systematic PBx with six to 24 random cores. • All patients were re-biopsied with a 'saturation' rPBx with 20-26 cores, with a median time to rPBx of 12 months. • All slides were reviewed by expert uropathologists., Results: • Plurifocal HGPIN (pHGPIN) was found in 115 patients and monofocal HGPIN (mHGPIN) was found in 147 patients. • In total, 108 and 154 patients, respectively, were submitted to >12-core initial PBx and ≤12-core initial PBx. • Overall PCa detection at rPBx was 31.7%. PSA level (7.7 vs 6.6 ng/mL; P= 0.031) and age (68 vs 64 years; P= 0.001) were significantly higher in patients with PCa at rPBx. • PCa detection was significantly higher in patients with a ≤12-core initial PBx than in those with a >12-core initial PBx (37.6% vs 23.1%; P= 0.01), as well as in patients with pHGPIN than in those with mHGPIN (40% vs 25.1%; P= 0.013). • At multivariable analysis, PSA level (P= 0.041; hazards ratio, HR, 1.08), age (P < 0.001; HR, 1.09), pHGPIN (P= 0.031; HR, 1.97) and ≤12-core initial PBx (P= 0.012; HR, 1.95) were independent predictors of PCa detection. • A nomogram including these four variables achieved 72% accuracy for predicting PCa detection after an initial HGPIN diagnosis., Conclusions: • PCa detection on saturation rPBx after an initial diagnosis of HGPIN is significantly higher in patients with a ≤12-core initial PBx than those with a >12-core initial PBx and in patients with pHGPIN than in those with mHGPIN. • We developed a simple prognostic tool for the prediction of PCa detection in patients with initial HGPIN diagnosis who were undergoing saturation rPBx., (© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.)
- Published
- 2012
- Full Text
- View/download PDF
36. Diagnosis of high-grade prostatic intraepithelial neoplasia: the impact of the number of biopsy cores at initial sampling on cancer detection after a saturation re-biopsy.
- Author
-
Roscigno M, Scattoni V, Freschi M, Raber M, Angiolilli D, Galosi A, Lacetera V, Montironi R, Muzzonigro G, Deho F, Feroldi L, Deiana G, Chinaglia D, Montorsi F, and Da Pozzo LF
- Subjects
- Aged, Aged, 80 and over, Biopsy methods, Biopsy statistics & numerical data, Humans, Male, Middle Aged, Retrospective Studies, Prostatic Intraepithelial Neoplasia pathology, Prostatic Neoplasms pathology
- Abstract
Objectives: To evaluate factors that may predict prostate cancer (PCa) detection after initial diagnosis of high-grade prostatic intraepithelial neoplasia (HGPIN) on 6-24 cores prostatic biopsies (PBx)., Material and Methods: We retrospectively evaluated 193 patients submitted from 1998 to 2007 to prostate re-biopsy after initial HGPIN diagnosis in three urologic departments. HGPIN diagnosis was obtained on initial systematic PBx with 6 to 24 random cores. All patients were re-biopsied with a "saturation" PBx with 18-26 cores with a median time to re-biopsy of 12 months. All slides were reviewed by expert uro-pathologists., Results: Plurifocal HGPIN (pHGPIN) was found in 103 patients and monofocal HGPIN (mHGPIN) in 90. Seventy-two and 121 patients were submitted to > 12-core initial biopsy and < or = 12-core, respectively. Overall PCa detection at re-biopsy was 28.4%. PSA (6.7 vs 8.5 ng/ml; p = 0.029) and age (64 vs 68 years; p = 0.005) were significantly higher in patients with PCa at re-biopsy. PCa detection was significantly higher in patients who underwent a < or = 12-core initial PBx than in those with > 12-core (35.5% vs 16.8%; p = 0.03), and in patients with pHGPIN than in those with mHGPIN (34.9% vs 21%; p = 0.035). At multivariable analysis, PSA value (p = 0.007; HR:1.18), prostate volume (p = 0.01; HR:0.966), age (p < 0.001; HR:1.15), pHGPIN (p = 0.003; HR:2.97) and < or = 12-core initial biopsy (p = 0.012; HR:3.62) were independent predictors of PC detection. We further analysed the 2 groups of patients submitted to < or = 12-core and > 12-core initial PBx. Plurifocal HGPIN and older age at biopsy were independent predictors in patients with < or = 12-core initial PBx. On the contrary, in patients with > 12-core initial biopsy, higher PSA values and lower prostate volume were independent predictors of PC detection., Conclusions: PCa detection on saturation re-biopsy after initial diagnosis of HGPIN is significantly higher in patients submitted to < or = 12-core than those submitted to > 12-core initial PBx. In patients with < or = 12-core initial biopsy pHGPIN and older age were predictors of PCa detection at re-biopsy. In patients with > 12-core initial biopsy, higher PSA values and lower prostate volume was associated to an increased risk of PCa detection at re-biopsy.
- Published
- 2010
37. Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation.
- Author
-
Salonia A, Rocchini L, Sacca' A, Pellucchi F, Ferrari M, Del Carro U, Ribotto P, Gallina A, Zanni G, Deho' F, Rigatti P, and Montorsi F
- Subjects
- Adolescent, Adult, Age Factors, Antidepressive Agents, Second-Generation pharmacology, Health Knowledge, Attitudes, Practice, Health Status Indicators, Humans, Italy, Male, Middle Aged, Paroxetine pharmacology, Selective Serotonin Reuptake Inhibitors pharmacology, Time Factors, Young Adult, Antidepressive Agents, Second-Generation therapeutic use, Ejaculation drug effects, Medication Adherence statistics & numerical data, Paroxetine therapeutic use, Selective Serotonin Reuptake Inhibitors therapeutic use, Sexual Dysfunction, Physiological drug therapy
- Abstract
Introduction: Selective serotonin reuptake inhibitors are the most widely used agents for delaying ejaculation in patients with premature ejaculation (PE)., Aim: The aim of this study was to assess the acceptance of and the discontinuation rate from paroxetine treatment in patients with lifelong PE., Methods: We analyzed the acceptance of and discontinuation rates of 93 consecutive potent patients (mean age, 37.6 years) seeking medical treatment for lifelong PE. The patients were assessed with detailed medical and sexual history, self-reported intravaginal ejaculatory latency time, self-administered International Index of Erectile Function, complete physical examination, and the Meares-Stamey test. The patients received a paroxetine prescription (10 mg daily for 21 days and then 20 mg as needed) for the first 3 months. Thereafter, the patients could either stay with the same on-demand treatment or take paroxetine 10 mg daily for 3 months. The patients were evaluated at 3 and 6 months, and requested to complete multiple-choice global assessment questions regarding specific reasons for eventual therapy discontinuation., Main Outcome Measures: The primary end point was acceptance and discontinuation rates for paroxetine treatment in patients seeking medical treatment for lifelong PE. The secondary end point was the reasons for nonacceptance of treatment or discontinuation., Results: Twenty-eight (30.10%) patients decided not to start paroxetine. Fear of using an "antidepressant drug" was the main reason (42.9%) for treatment nonacceptance. Twenty (30.8%) patients who initiated therapy eventually discontinued it. Treatment effect below expectations was the main reason of treatment dropout (75%) during the first 3 months, followed by temporary loss of interest in sex because of relationship issues (15%) and side effects (10%). Of the patients who continued treatment, 77.8% preferred daily paroxetine, while 22.2% continued as-needed therapy., Conclusions: Thirty percent of lifelong PE patients seeking medical treatment for complaints of early ejaculation freely decided not to start any paroxetine treatment, and roughly 30% of patients who started therapy eventually discontinued it.
- Published
- 2009
- Full Text
- View/download PDF
38. Anatomical radical retropubic prostatectomy in patients with a preexisting three-piece inflatable prosthesis: a series of case reports.
- Author
-
Deho' F, Salonia A, Briganti A, Zanni G, Gallina A, Rokkas K, Guazzoni G, Rigatti P, and Montorsi F
- Subjects
- Aged, Equipment Safety, Erectile Dysfunction etiology, Feasibility Studies, Follow-Up Studies, Humans, Male, Penile Implantation instrumentation, Prostatic Neoplasms complications, Prostatic Neoplasms surgery, Prosthesis Design, Erectile Dysfunction therapy, Penile Prosthesis adverse effects, Penis anatomy & histology, Prostatectomy methods
- Abstract
Introduction: Only few reports addressed the outcome of patients submitted to anatomical radical retropubic prostatectomy (RRP) with an indwelling inflatable penile prosthesis (IPP)., Aim: To assess the feasibility and safety of RRP in patients with clinically localized prostate cancer and a previously implanted with an IPP., Main Outcome Measures: We evaluated the surgical parameters and the follow-up functional results in this particular patient population., Methods: Four patients previously submitted to IPP implant for severe erectile dysfunction underwent RRP for organ-confined prostate cancer. Patients' charts were carefully reviewed to investigate pre- and perioperative details. Patients were evaluated by the International Index of Erectile Function (IIEF) preoperatively and at 6 months postoperatively. Patients were then contacted to assess long-term functional and oncological outcome., Results: The outcome of the procedures was comparable to a normal population in terms of operating time, estimated blood loss, hospitalization time, and pathological outcome. No injury to the preexisting penile implant was reported. Continence was obtained in 3 (75%) patients at catheter removal, and in 1 (25%) patient at the 1-month follow-up. No major intra- and postoperative complications were reported. All patients were able to use their prosthesis after RRP. No statistical difference in pre- and post-RRP EF domain scores was found., Conclusion: The presence of an IPP in patients with prostate cancer is not a contraindication to perform an anatomical RRP. Surgery can be performed safely without injuring the implant and the clinical outcome in these patients is satisfactory. Postoperative implant use is not affected by RRP.
- Published
- 2009
- Full Text
- View/download PDF
39. Prophylaxis of erectile function after radical prostatectomy with phosphodiesterase type 5 inhibitors.
- Author
-
Deho F, Gallina A, Salonia A, Briganti A, Suardi N, Zanni G, Guazzoni G, Rigatti P, and Montorsi F
- Subjects
- Humans, Male, Erectile Dysfunction etiology, Erectile Dysfunction prevention & control, Phosphodiesterase 5 Inhibitors, Phosphodiesterase Inhibitors therapeutic use, Postoperative Complications etiology, Postoperative Complications prevention & control, Prostatectomy
- Abstract
Erectile dysfunction (ED) is one of the most challenging complications associated with radical prostatectomy (RP) for clinically localized prostate cancer. Currently, a broad spectrum of therapeutic options are available to improve sexual health after surgical treatment. Several basic science reports highlighted a potential role for phosphodiesterase type 5 inhibitors in the prevention of endothelial damage related to ischemia reperfusion and/or denervation following surgery. Recent studies have shown that pharmacological prophylaxis soon after RP can significantly improve the rate at which erectile function is recovered after surgery. Use of on-demand treatments for ED in patients who have undergone RP has been shown to be highly effective. In this context, pharmacological prophylaxis potentially may have a significantly expanded role in future strategies aimed at preserving postoperative erectile function. We analyzed the factors affecting erectile function after RP and evaluated the evidence suggesting the role of pharmacological prophylaxis and treatment of ED after surgery.
- Published
- 2009
- Full Text
- View/download PDF
40. Severe vascular complication after implantation of a three-piece inflatable penile prosthesis.
- Author
-
Deho' F, Henry GD, Marone EM, Sacca' A, Chiesa R, Rigatti P, and Montorsi F
- Subjects
- Aged, Body Mass Index, Constriction, Pathologic diagnosis, Constriction, Pathologic surgery, Humans, Male, Prosthesis Design, Prosthesis Fitting, Pulmonary Embolism prevention & control, Reoperation methods, Vena Cava Filters, Iliac Artery pathology, Iliac Vein pathology, Ischemia diagnosis, Ischemia surgery, Leg blood supply, Penile Implantation adverse effects, Penile Prosthesis, Postoperative Complications diagnosis, Postoperative Complications surgery, Prosthesis Failure, Tomography, X-Ray Computed, Ultrasonography, Doppler, Color, Venous Thrombosis diagnosis, Venous Thrombosis surgery
- Abstract
We report a case of acute arterial ischemia and deep venous thrombosis due to compression of the external iliac vein and artery by the reservoir of a three-piece inflatable penile prosthesis.
- Published
- 2008
- Full Text
- View/download PDF
41. Improving the preservation of the urethral sphincter and neurovascular bundles during open radical retropubic prostatectomy.
- Author
-
Montorsi F, Salonia A, Suardi N, Gallina A, Zanni G, Briganti A, Deho' F, Naspro R, Farina E, and Rigatti P
- Subjects
- Aged, Biomarkers, Tumor blood, Biopsy, Needle, Follow-Up Studies, Humans, Immunohistochemistry, Male, Middle Aged, Muscle, Smooth physiology, Neoplasm Staging, Penis innervation, Postoperative Complications prevention & control, Prostate-Specific Antigen blood, Prostatectomy adverse effects, Risk Assessment, Treatment Outcome, Erectile Dysfunction prevention & control, Prostatectomy methods, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery, Urinary Incontinence prevention & control
- Abstract
Objectives: To describe a technique for open nerve-sparing radical retropubic prostatectomy., Methods: The technique basically implies incising the levator and prostatic fasciae high anteriorly (1 and 11 o'clock positions) over the prostate, developing the plane between the prostatic capsule and prostatic fascia, and displacing the neurovascular network localized between the two fasciae laterally. This allows for a minimal-touch dissection of the external urethral sphincter and a very efficient dissection of the neurovascular bundles at the level of membranous urethra and prostatic apex., Results: Forty-two patients underwent a bilateral nerve-sparing operation and were followed- up for 6 months. Six patients (14.3%) had positive margins: 4 patients had pT2 disease (in all, the positive margin was monofocal) and 2 patients had pT3 disease (both had multifocal positive margins). Continence (defined as being dry or having one pad remain dry for 24 hours) was achieved in 44% of patients at catheter removal, and in 60%, 72%, and 90% of patients at the 1-, 3-, and 6-month follow-up visits. Potency (defined as an erectile function domain score > or =26) was obtained in 15%, 40%, and 52% of patients at the 1-, 3-, and 6-month follow-up visits. All patients used a PDE5-inhibitor during the investigation period., Conclusions: These preliminary results suggest that the high incision of the levator and prostatic fasciae may facilitate efficient preservation of the external urethral sphincter and the neurovascular bundles innervating the corpora cavernosa and the sphincter.
- Published
- 2005
- Full Text
- View/download PDF
42. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
- Author
-
Briganti A, Salonia A, Deho' F, Zanni G, Barbieri L, Rigatti P, and Montorsi F
- Subjects
- 3',5'-Cyclic-GMP Phosphodiesterases, Carbolines therapeutic use, Cyclic Nucleotide Phosphodiesterases, Type 5, Humans, Imidazoles therapeutic use, Male, Phosphodiesterase Inhibitors pharmacology, Piperazines therapeutic use, Purines, Sildenafil Citrate, Sulfones therapeutic use, Tadalafil, Triazines therapeutic use, Vardenafil Dihydrochloride, Erectile Dysfunction drug therapy, Phosphodiesterase Inhibitors therapeutic use, Phosphoric Diester Hydrolases
- Abstract
Erectile dysfunction (ED) affects the sexual lives of millions of men. The first-line oral pharmacotherapy for most ED patients is phosphodiesterase type-5 (PDE-5) inhibitors, of which three are available. Sildenafil is the most widely prescribed oral agent for ED and has a very satisfactory efficacy-safety profile in all patient categories. Tadalafil and vardenafil were introduced in the European Union and in the United States in 2003 and 2004, respectively. The three PDE-5 inhibitors share many pharmacological and clinical characteristics, and each has unique features. This review, which is based on the contemporary literature on PDE-5 inhibitors, describes the chemical, pharmacological, and clinical features of sildenafil, vardenafil, and tadalafil. The first section reviews the pathophysiology of penile erection and PDE-5 inhibitor pharmacology. The second section summarizes data regarding efficacy and safety of the three drugs in treating ED in the general population as well as in selected patient categories.
- Published
- 2005
- Full Text
- View/download PDF
43. Overall clinical outcomes after nerve and seminal sparing radical cystectomy for the treatment of organ confined bladder cancer.
- Author
-
Colombo R, Bertini R, Salonia A, Naspro R, Ghezzi M, Mazzoccoli B, Deho' F, Montorsi F, and Rigatti P
- Subjects
- Adult, Cystectomy adverse effects, Erectile Dysfunction epidemiology, Erectile Dysfunction etiology, Erectile Dysfunction prevention & control, Follow-Up Studies, Humans, Male, Middle Aged, Seminal Vesicles, Treatment Outcome, Urinary Bladder innervation, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms physiopathology, Urodynamics, Cystectomy methods, Urinary Bladder Neoplasms surgery
- Abstract
Purpose: We assessed postoperative clinical outcomes such as day and nighttime urinary continence and overall sexual function in patients who underwent nerve and seminal sparing cystectomy with ileocapsuloplasty compared with patients after standard cystoprostatectomy with similar orthotopic urinary reservoir., Materials and Methods: A total of 27 patients (mean age 52 years, range 36 to 61) with superficial high risk or muscular invasive T2 bladder cancer underwent radical nerve and seminal sparing cystectomy with ileocapsule anastomosis. Postoperative clinical outcomes such as urinary continence, voiding patterns and urodynamic parameters were evaluated at 3, 6 and 12 months, while overall sexual function was determined at baseline and at 6 and 12-month followup., Results: Nerve and seminal sparing cystectomy provides better outcomes in terms of urinary and urodynamic parameters compared to standard cystoprostatectomy. Furthermore, fully normal postoperative erectile function and satisfactory overall sexual quality of life were documented at early and delayed followup in all patients. A retrograde ejaculation with reliable sperm retrieval from urine was also documented., Conclusions: Although these findings need to be confirmed in a larger patient population, when respecting rigorous patient selection criteria and careful postoperative surveillance, nerve and seminal sparing cystectomy seems to offer satisfactory clinical and functional outcomes. From an oncological point of view, long-term followup is of paramount importance to confirm whether this surgical procedure can be proposed as a valid choice of treatment for young, fully potent and socially active patients with organ confined bladder cancer.
- Published
- 2004
- Full Text
- View/download PDF
44. Peyronie's disease: a review.
- Author
-
Briganti A, Salonia A, Deho F, Zanni G, Rokkas K, Rigatti P, and Montorsi F
- Subjects
- Humans, Male, Penile Induration physiopathology, Penile Induration diagnosis, Penile Induration therapy
- Abstract
Purpose of Review: This review is aimed to summarize the most recent findings about this topic, by reviewing the literature published in 2002 and 2003 regarding the epidemiology, pathophysiology, diagnosis and treatment of Peyronie's disease., Recent Findings: Although many aspects in pathophysiology, diagnosis, medical and surgical treatment of Peyronie's disease still remain under debate, recent interesting advances have been made regarding the different aspects of this condition. Topical and systemic medical therapies have been associated with varying degrees of results, depending on modalities and timing of the treatment itself. A wide range of surgical modalities have been recently developed, although the ideal surgical procedure especially in case of severe and complex curvature does not seem to be reached yet. Furthermore this condition is often associated with psychological distress that could be responsible for performance anxiety, leading to improvement of abnormalities in erectile functioning eventually associated with Peyronie's disease., Summary: Peyronie's disease consists of an acquired penile deformity caused by the formation of fibrous plaques within the tunica albuginea, leading to bio-mechanical and vascular abnormalities. In the last decade numerous advances have been made regarding pathophysiology, diagnosis and treatment of this condition, allowing for improved patient clinical prognosis. Nevertheless, although improvements in medical and surgical therapies have substantially increased the successful patients' outcome rate, Peyronie's disease is still not completely understood and its treatment remains often frustrating for the practicing urologist. Clinical presentations of this disease include penile deformities or shortening during erection, painful erection, palpable plaque or induration throughout the length of the penile shaft and erectile dysfunction.
- Published
- 2003
- Full Text
- View/download PDF
45. Brain activation patterns during video sexual stimulation following the administration of apomorphine: results of a placebo-controlled study.
- Author
-
Montorsi F, Perani D, Anchisi D, Salonia A, Scifo P, Rigiroli P, Deho F, De Vito ML, Heaton J, Rigatti P, and Fazio F
- Subjects
- Administration, Sublingual, Aged, Brain drug effects, Brain physiology, Brain Mapping, Double-Blind Method, Erotica, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Penile Erection physiology, Reference Values, Sensitivity and Specificity, Video Recording, Apomorphine administration & dosage, Arousal drug effects, Erectile Dysfunction diagnosis, Erectile Dysfunction drug therapy, Magnetic Resonance Imaging methods, Penile Erection drug effects
- Abstract
Objectives: To evaluate the in vivo effect of apomorphine sublingual versus placebo on cortical and subcortical brain activation during video sexual stimulation., Methods: Ten patients with psychogenic erectile dysfunction and six potent controls underwent functional magnetic resonance of the brain during video sexual stimulation after the administration of either apomorphine sublingual 4mg or placebo following a randomized, double blind design. Functional magnetic resonance sessions were performed with a 7-day interval., Results: In potent controls, viewing erotic versus neutral films induced bilateral activations in a network of occipito-parietal and temporal inferior regions, in dorsolateral and premotor frontal cortex, in anterior temporal limbic areas and the thalamus, which were comparable to the patient activations during erotic stimulation in the placebo condition. However, a striking difference was found in patients, who demonstrated a significant and extended activation in the cingulate gyrus, frontal mesial and frontal basal cortex, bilaterally, in comparison with potent controls. These activated neural systems were modulated by apomorphine administration which produced a picture that was similar to the one seen in potent controls. In patients with spychogenic erectile dysfunction apomorphine sublingual caused an increase in the extension of the activated networks, plus additional activation foci in subcortical and deep structures, namely in the nucleus accumbens, hypothalamus and mesencephalon: this activation was greater than that seen with placebo. Interestingly, a down-regulation in the frontal basal and temporal limbic cortex was present as shown by a decrease of functional magnetic resonance imaging signal reflecting a deactivation of these regions., Conclusions: Apomorphine significantly enhances the activation of cortical and subcortical brain function during video sexual stimulation. Patients with psychogenic erectile dysfunction may have an underlying functional abnormality of the brain acting as a previously unrecognised aetiological factor.
- Published
- 2003
- Full Text
- View/download PDF
46. Pharmacological management of erectile dysfunction.
- Author
-
Montorsi F, Salonia A, Deho' F, Cestari A, Guazzoni G, Rigatti P, and Stief C
- Subjects
- Administration, Oral, Adrenergic alpha-Antagonists administration & dosage, Alprostadil administration & dosage, Apomorphine administration & dosage, Drug Combinations, Humans, Imidazoles administration & dosage, Injections, Male, Papaverine administration & dosage, Phentolamine administration & dosage, Phosphodiesterase Inhibitors administration & dosage, Piperazines administration & dosage, Purines, Sildenafil Citrate, Sulfones, Tadalafil, Triazines, Vardenafil Dihydrochloride, Vasodilator Agents administration & dosage, Carbolines, Erectile Dysfunction drug therapy
- Abstract
Erectile dysfunction (ED) is a common medical condition that affects the sexual life of millions of men worldwide. Many drugs are now available for treating ED; oral pharmacotherapy represents the first-line option for most patients with ED. Sildenafil, an inhibitor of the enzyme phosphodiesterase type 5, is currently the most widely prescribed oral agent and has a very satisfactory efficacy-safety profile in all patient categories. Apomorphine SL is a dopamine D1- and D2-receptor agonist which has recently been approved for marketing in Europe. It is best selected for treating patients with mild to moderate ED. Vardenafil and tadalafil are new phosphodiesterase type 5 inhibitors which are expected to be approved this year. Both of them have significant positive efficacy-safety profiles. Patients who do not respond to oral pharmacotherapy or who cannot use it are good candidates for intracavernosal and intraurethral therapy. Alprostadil is the most widely used drug, both for injection therapy and for the intraurethral route. The efficacy of second-line treatment is high but the attrition rate remains significant.
- Published
- 2003
- Full Text
- View/download PDF
47. The ageing male and erectile dysfunction.
- Author
-
Montorsi F, Salonia A, Deho F, Briganti A, and Rigatti P
- Subjects
- Erectile Dysfunction epidemiology, Humans, Male, Prevalence, Aging physiology, Erectile Dysfunction physiopathology, Erectile Dysfunction therapy
- Abstract
Erectile dysfunction (ED) is common in the ageing man and reliable therapies are needed. The pathophysiology of erectile dysfunction in this patient group mainly includes chronic ischaemia, which triggers the deterioration of cavernous smooth muscle and the development of corporeal fibrosis. The assessment of the ageing man with erectile dysfunction who seeks medical treatment should include a thorough medical and sexual history, a systemic and focused physical examination and selected blood tests. An extensive discussion of the various therapeutic options should follow in order to allow the patient to identify the most suitable alternative. Oral drug therapy represents a safe and efficacious option for most elderly patients.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.